Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299560 | 0.95 | HPGD (0.64) | HPGDRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL3466095 | 0.82 | ALDH1A1 (0.60) | HPGDSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL7694361 | 0.82 | ALDH1A1 (0.60) | HPGDSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL8105528 | 0.82 | ALDH1A1 (0.60) | HPGDSMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL3822824 | 0.81 | ALDH1A1 (0.50) | HPGDRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL8338592 | 0.81 | HPGD (0.65) | HPGDRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL23054249 | 0.80 | RAB9A (0.54) | HPGDRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL21051399 | 0.80 | RAB9A (0.58) | HPGDRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL1710059 | 0.80 | RAB9A (0.68) | HPGDRAB9ANPC1SMN1; SMN2LMNA | |
| SCHEMBL21051390 | 0.80 | RAB9A (0.58) | HPGDRAB9ANPC1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110791119-A | Method for preparing disperse red SBWF | 江苏海洋大学 | 2020-02-14 | — | — | CN | claimed |
| CN-120005420-A | Disperse dye for superfine denier fiber and synthesis method thereof | 青岛大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-110791119-A | Method for preparing disperse red SBWF | 江苏海洋大学 | 2020-02-14 | — | — | CN | disclosed |
| CN-110791119-A | Method for preparing disperse red SBWF | 江苏海洋大学 | 2020-02-14 | — | — | CN | disclosed |
| EP-2861570-B1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | UNIV RUTGERS (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9592221-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592221-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| US-9315495-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315495-B2 | Antibacterial agents: aryl myxopyronin derivatives | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150197512-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | PROVID PHARMACEUTICALS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197512-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | PROVID PHARMACEUTICALS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-1940823-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| WO-1999007693-A1 | BENZOTHIOPHENES | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | HPGD 2223/4885RAB9A 3913/4885NPC1 3918/4885 |
| US-20150197512-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | FBL, POLRMT, POLR1C | HPGD 2441/4885RAB9A 3878/4885NPC1 3899/4885 |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | HPGD 2634/4885RAB9A 2174/4885NPC1 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.